



Fair Pricing Forum 2021

Meeting Report

Fair Pricing Forum 2021 meeting report



**World Health
Organization**

Fair pricing forum 2021 meeting report

ISBN 978-92-4-003858-5 (electronic version)

ISBN 978-92-4-003859-2 (print version)

© World Health Organization 2021

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”.

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization (<http://www.wipo.int/amc/en/mediation/rules/>).

Suggested citation. Fair pricing forum 2021 meeting report. Geneva: World Health Organization; 2021. Licence: [CC BY-NC-SA 3.0 IGO](https://creativecommons.org/licenses/by-nc-sa/3.0/igo).

Cataloguing-in-Publication (CIP) data. CIP data are available at <http://apps.who.int/iris>.

Sales, rights and licensing. To purchase WHO publications, see <http://apps.who.int/bookorders>. To submit requests for commercial use and queries on rights and licensing, see <http://www.who.int/about/licensing>.

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

This publication contains the report of the Fair Pricing Forum 2021 and does not necessarily represent the decisions or policies of WHO.

Contents

Contents	iii
Acknowledgements	iv
Executive summary	1
Overview.....	1
Main themes from the Forum.....	1
Next steps	1
Overview.....	2
Background	2
Forum objectives and agenda	2
At the Forum	2
Main themes arising from the Forum.....	3
Transparency is essential for improving access to current and future innovations.....	3
Collaboration across countries can facilitate affordable access	3
The public sector could play a greater role in ensuring affordability and driving future innovations.....	3
Stakeholders must clarify definitions and metrics of affordability.....	4
Further policymaking is needed to ensure affordable access to medical devices and in vitro diagnostics	4
Session summaries.....	5
Plenary sessions.....	5
Parallel sessions	8
References.....	17
Annex 1: List of Forum participants.....	17
Annex 2: Forum agenda	42
Annex 3: Members of Fair Pricing Forum 2021 preparatory working groups.....	50

Acknowledgements

The Fair Pricing Forum 2021 was made possible through a collaboration among members of secretariats at the Ministry of Health of the Government of Argentina, Pan American Health Organization, and the Department of Health Products Policy and Standards of the World Health Organization (WHO).

WHO would like to express special thanks to members of the two technical preparatory working groups, as well as the speakers, panellists and participants who provided rich contributions to the Forum. These contributors can be found in Annexes to this document.

Executive summary

Overview

The third biennial Fair Pricing Forum was held online on 13-15 and 20-22 April 2021 to continue the tradition of encouraging dialogue among various stakeholders, with the following objectives:

- i. To share countries' experiences, including from the coronavirus disease (COVID-19) pandemic, in ensuring affordability and transparency of prices and costs of health products
- ii. To advance discussion and knowledge on approaches and system factors pertaining to the pricing and R&D of pharmaceutical products for enhancing affordability, transparency, and innovation, and achieving health sustainable development goals
- iii. To increase support for countries to achieve more affordable and fairer access to pharmaceutical products during the COVID-19 pandemic and beyond.

In total, more than 850 people from 125 Member States participated in the Forum and pre-Forum webinar.

Main themes from the Forum

- Transparency is essential for improving access to current and future innovations to inform and enforce pricing and innovation policies, as well as ensure accountability
- Collaboration across countries can facilitate affordable access by leveraging collective positions, joint technical assessments and decision-making, and sharing market information
- Interest is growing for the public sector to play a greater role in ensuring affordability and driving innovation
- Stakeholders must clarify definitions and metrics of affordability to facilitate global discourse on access
- Further policymaking is needed to ensure affordable access to medical devices and in vitro diagnostics, with unique and complex market features compared to medicines/vaccines markets

Next steps

Additional work is needed to accelerate access to effective health products and ensure prices are affordable to health systems and patients. This includes making better use of the collective power of countries, investing in innovation to meet public health needs, determining the true value of health products, and efficient regulatory processes and legal tools to improve early access and affordability. Learnings from the COVID-19 pandemic in accelerating development and access can contribute to longer-term solutions to many of these challenges.

Specific areas for further stakeholder action are highlighted throughout the document. Key WHO activities planned before the next Fair Pricing Forum in 2023 include:

- Create a knowledge hub for stakeholders to reach experts, share views and information on how to improve availability, pricing, and affordability of health technologies with increasing impact on access
- Launch an updated electronic tool, MedMon, designed to monitor availability and prices of health products in countries, as open access and available to all
- Support the development of national or regional price monitoring systems
- Strengthen capacity building of national policy makers by hosting further webinars and trainings

Overview

Background

In 2019, World Health Assembly resolution WHA72(8) *Improving the transparency of markets for medicines, vaccines, and other health products* requested the WHO Director-General, among other requests, “to continue WHO’s efforts to biennially convene the Fair Pricing Forum with Member States and all relevant stakeholders to discuss the affordability and transparency of prices and costs relating to health products”.

The 2021 Forum was held under this mandate to continue the tradition of encouraging rich dialogue among various stakeholders, following the first Forum in Amsterdam (The Netherlands) in 2017, and the second Forum in Johannesburg (South Africa) in 2019.

Forum objectives and agenda

The Forum agenda was informed by three objectives:


- i. To share countries’ experiences, including from the coronavirus disease (COVID-19) pandemic, in ensuring affordability and transparency of prices and costs of health products
- ii. To advance discussion and knowledge on

The Forum was organized with the support from the Government of Argentina. Two preparatory working groups of experts contributed to the contents of the agenda, including two discussion papers.

At the Forum

The Forum was held online on 13-15 and 20-22 April 2021. In total, more than 850 people from 125 Member States registered to participate in the Forum and pre-Forum webinar. Over the event, more than 150 speakers, panellists and moderators contributed to 14 plenary sessions, parallel sessions, and pre-Forum webinar, as illustrated below.

Figure 1: Fair Pricing Forum 2021 in numbers



预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_23510

